Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (332648) 332648
Book Review (63765) 63765
Publication (36401) 36401
Newsletter (12770) 12770
Newspaper Article (7198) 7198
Book Chapter (3660) 3660
Conference Proceeding (1128) 1128
Book / eBook (1018) 1018
Dissertation (637) 637
Government Document (199) 199
Reference (151) 151
Web Resource (112) 112
Magazine Article (105) 105
Trade Publication Article (55) 55
Data Set (29) 29
Streaming Video (27) 27
Transcript (10) 10
Paper (9) 9
Presentation (4) 4
Patent (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (282826) 282826
humans (182961) 182961
animals (160043) 160043
proteins (73385) 73385
biochemistry & molecular biology (69289) 69289
mice (69005) 69005
phosphorylation (65314) 65314
cell biology (63043) 63043
signal transduction (59671) 59671
male (53827) 53827
female (52642) 52642
oncology (50902) 50902
research (45760) 45760
cancer (43624) 43624
expression (41098) 41098
kinases (37526) 37526
rats (34024) 34024
activation (33947) 33947
gene expression (33765) 33765
apoptosis (32136) 32136
analysis (31175) 31175
mutation (29616) 29616
cells, cultured (27913) 27913
physiological aspects (26621) 26621
cell line, tumor (26340) 26340
molecular sequence data (26149) 26149
article (26008) 26008
cell line (24800) 24800
genetic aspects (24676) 24676
cells (24441) 24441
amino acid sequence (23676) 23676
neurosciences (23500) 23500
tyrosine (22576) 22576
protein (21839) 21839
immunology (21587) 21587
multidisciplinary sciences (21579) 21579
protein binding (20964) 20964
research article (20677) 20677
middle aged (20293) 20293
adult (19347) 19347
protein-tyrosine kinases - metabolism (18329) 18329
health aspects (18265) 18265
tumors (17439) 17439
pharmacology & pharmacy (17309) 17309
signal transduction - drug effects (17274) 17274
genes (17252) 17252
biology (17094) 17094
medicine (16966) 16966
protein kinases (16911) 16911
gene-expression (16873) 16873
rodents (16239) 16239
aged (16034) 16034
tyrosine kinase (15962) 15962
signal transduction - physiology (15844) 15844
hematology (15089) 15089
receptor (15051) 15051
physiology (14841) 14841
genetics & heredity (14801) 14801
immunohistochemistry (14634) 14634
abridged index medicus (14609) 14609
cell proliferation (14134) 14134
care and treatment (14092) 14092
biochemistry (14076) 14076
in-vivo (14053) 14053
biophysics (13658) 13658
blotting, western (13460) 13460
base sequence (13246) 13246
tyrosine phosphorylation (13222) 13222
gene (13211) 13211
science (13051) 13051
metastasis (13048) 13048
growth (12892) 12892
transfection (12877) 12877
endocrinology & metabolism (12777) 12777
signal-transduction (12736) 12736
in-vitro (12687) 12687
enzyme inhibitors - pharmacology (12666) 12666
identification (12475) 12475
binding sites (12270) 12270
medicine, research & experimental (12182) 12182
mice, inbred c57bl (12020) 12020
inhibition (11937) 11937
enzyme activation (11866) 11866
life sciences (11729) 11729
oxidative stress (11723) 11723
inflammation (11701) 11701
cell cycle (11677) 11677
binding (11516) 11516
angiogenesis (11462) 11462
ligands (11445) 11445
enzymes (11419) 11419
tumor cells, cultured (11224) 11224
models, biological (11205) 11205
vascular endothelial growth factor (11195) 11195
development and progression (11193) 11193
epidermal growth factor (11188) 11188
antineoplastic agents - pharmacology (10688) 10688
molecular biology (10653) 10653
breast cancer (10515) 10515
receptors (10492) 10492
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (636) 636
Online Resources - Online (116) 116
UofT at Mississauga - Stacks (103) 103
Collection Dvlpm't (Acquisitions) - Vendor file (61) 61
UTL at Downsview - May be requested (50) 50
UofT at Scarborough - Stacks (40) 40
Chemistry (A D Allen) - Stacks (39) 39
Collection Dvlpm't (Acquisitions) - Closed Orders (39) 39
Engineering & Comp. Sci. - Stacks (21) 21
Earth Sciences (Noranda) - Stacks (16) 16
UofT at Scarborough - Withdrawn (7) 7
St. Michael's College (John M. Kelly) - 2nd Floor (5) 5
Trinity College (John W Graham) - Stacks (5) 5
Gerstein Science - Circulation Desk (4) 4
Royal Ontario Museum - Stacks (4) 4
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (3) 3
UofT at Mississauga - Reference (3) 3
Gerstein Science - Missing (2) 2
Media Commons - Microtexts (2) 2
Physics - Stacks (2) 2
UofT at Mississauga - Missing (2) 2
Victoria University E.J. Pratt - Oversize (2) 2
Chemistry (A D Allen) - May be requested in 6-10 wks (1) 1
Chemistry (A D Allen) - Theses (1) 1
Collection Dvlpm't (Acquisitions) - Cancelled Order (1) 1
Earth Sciences (Noranda) - Circulation Desk (1) 1
Earth Sciences (Noranda) - Oversize (1) 1
Engineering & Comp. Sci. - Reference (1) 1
Gerstein Science - Not Returned (1) 1
Gerstein Science - Reference (1) 1
Gerstein Science - Reserve desk (1) 1
Gerstein Science - Theses (1) 1
Law (Bora Laskin) - Stacks (1) 1
Physics - Course Reserves (1) 1
Scarborough Hospital - Online (1) 1
St. Michael's Hospital - Stacks (1) 1
Trinity College (John W Graham) - Oversize (1) 1
UofT at Mississauga - Circulation Desk (1) 1
UofT at Scarborough - May be requested in 6-10 wks (1) 1
Victoria University E.J. Pratt - Circulation Desk (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (353122) 353122
Chinese (977) 977
Japanese (793) 793
French (562) 562
German (363) 363
Russian (202) 202
Spanish (182) 182
Polish (80) 80
Korean (60) 60
Hungarian (59) 59
Czech (39) 39
Portuguese (36) 36
Italian (24) 24
Dutch (20) 20
Swedish (16) 16
Danish (12) 12
Finnish (11) 11
Norwegian (9) 9
Turkish (9) 9
Ukrainian (7) 7
Bulgarian (5) 5
Serbian (5) 5
Slovak (4) 4
Romanian (3) 3
Arabic (2) 2
Croatian (2) 2
Catalan (1) 1
Hebrew (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Resistance to tyrosine kinase inhibitors
by Focosi, Daniele
2016, Resistance to Targeted Anti-Cancer Therapeutics, ISBN 9783319460901, Volume 10
Chemotherapy | Inhibitors | Protein-tyrosine kinase | Therapeutic use | Cancer
Web Resource
Details down arrow
2. Receptor tyrosine kinases
: methods and protocols
by Germano, Serena and Springer Science+Business Media
2015, Methods in molecular biology, ISBN 1493917889, Volume 1233
Protein-tyrosine kinase | Receptor Protein-Tyrosine Kinases
Web Resource
Details down arrow
3. Receptor tyrosine kinases
: methods and protocols
by Germano, Serena
2015, Methods in molecular biology, ISBN 1493917889, Volume 1233
Receptor Protein-Tyrosine Kinases
Web Resource
Details down arrow
4. Full Text Diversification of TAM receptor tyrosine kinase function
by Zagórska, Anna and Zagórska, Anna and Través, Paqui G and Lew, Erin D and Dransfield, Ian and Lemke, Greg
Nature immunology, ISSN 1529-2908, 10/2014, Volume 15, Issue 10, pp. 920 - 928
The clearance of apoptotic cells is critical for both tissue homeostasis and the resolution of inflammation. We found that the TAM receptor tyrosine kinases... 
BREAST-CANCER | IMMUNE-RESPONSE | CLEARANCE | DENDRITIC CELLS | PLASMA-CONCENTRATIONS | SOLUBLE FORM | AXL | APOPTOTIC CELLS | IN-VIVO | IMMUNOLOGY | TYRO-3 FAMILY | Gene Expression - drug effects | Dendritic Cells - immunology | Receptor Protein-Tyrosine Kinases - immunology | Immunoblotting | Lipopolysaccharides - immunology | Intercellular Signaling Peptides and Proteins - metabolism | Bone Marrow Cells - immunology | c-Mer Tyrosine Kinase | Gene Expression - immunology | Proto-Oncogene Proteins - immunology | Dendritic Cells - metabolism | Macrophages - immunology | Proto-Oncogene Proteins - metabolism | Microscopy, Electron, Scanning | Mice, Inbred C57BL | Cells, Cultured | Intercellular Signaling Peptides and Proteins - genetics | Phagocytosis - immunology | Proto-Oncogene Proteins - genetics | Protein Binding - immunology | Receptor Protein-Tyrosine Kinases - metabolism | Reverse Transcriptase Polymerase Chain Reaction | Mice, Knockout | Microscopy, Confocal | Macrophages - metabolism | Animals | Apoptosis - immunology | Receptor Protein-Tyrosine Kinases - genetics | Dendritic Cells - ultrastructure | Lipopolysaccharides - pharmacology | Bone Marrow Cells - metabolism | Intercellular Signaling Peptides and Proteins - immunology | Cell receptors | Regulation | Genetic aspects | Immune response | Properties | Phosphotransferases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
by Woyach, Jennifer A and Furman, Richard R and Liu, Ta-Ming and Ozer, Hatice Gulcin and Zapatka, Marc and Ruppert, Amy S and Xue, Ling and Li, Daniel Hsieh-Hsin and Steggerda, Susanne M and Versele, Matthias and Dave, Sandeep S and Zhang, Jenny and Yilmaz, Ayse Selen and Jaglowski, Samantha M and Blum, Kristie A and Lozanski, Gerard and Lozanski, Arletta and James, Danelle F and Barrientos, Jacqueline C and Lichter, Peter and Stilgenbauer, Stephan and Buggy, Joseph J and Chang, Betty Y and Johnson, Amy J and Byrd, John C
The New England Journal of Medicine, ISSN 0028-4793, 06/2014, Volume 370, Issue 24, pp. 2286 - 2294
In some patients with CLL, resistance to the BTK inhibitor ibrutinib develops. Two classes of resistance mutations have been found: the more common involves... 
POINT MUTATIONS | MEDICINE, GENERAL & INTERNAL | THERAPEUTIC TARGET | ACQUIRED-RESISTANCE | PCI-32765 | CHRONIC LYMPHOCYTIC-LEUKEMIA | CLINICAL RESISTANCE | GENE MUTATION | ANTIGEN RECEPTOR | CANCER | CHRONIC MYELOID-LEUKEMIA | Recurrence | Phospholipase C gamma - metabolism | Pyrazoles - therapeutic use | Humans | Middle Aged | Binding Sites - genetics | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Pyrimidines - pharmacology | Receptors, Antigen, B-Cell - metabolism | Sequence Analysis, DNA | Exome | Point Mutation | Drug Resistance, Neoplasm - genetics | Protein-Tyrosine Kinases - genetics | Pyrimidines - therapeutic use | Phospholipase C gamma - genetics | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Pyrazoles - pharmacology | Tyrosine | Cysteine | Chronic lymphatic leukemia | Serine | Leukemia | Genomes | Lymphatic leukemia | Kinases | Bruton's tyrosine kinase | Lymphocytes B | Mutation | Lymphocytosis | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma
by Snuderl, Matija and Fazlollahi, Ladan and Le, Long P and Nitta, Mai and Zhelyazkova, Boryana H and Davidson, Christian J and Akhavanfard, Sara and Cahill, Daniel P and Aldape, Kenneth D and Betensky, Rebecca A and Louis, David N and Iafrate, A. John
Cancer Cell, ISSN 1535-6108, 2011, Volume 20, Issue 6, pp. 810 - 817
Tumor heterogeneity has been implicated in tumor growth and progression as well as resistance to therapy. We present an example of genetic heterogeneity in... 
HETEROGENEITY | VEGFR2 | EVOLUTION | ONCOLOGY | KIT | CANCER | CELL BIOLOGY | Proto-Oncogene Proteins c-met - metabolism | Receptor, Epidermal Growth Factor - genetics | Receptor, Platelet-Derived Growth Factor alpha - metabolism | Humans | Middle Aged | Brain Neoplasms - pathology | Brain Neoplasms - genetics | Male | Brain Neoplasms - metabolism | Genetic Heterogeneity | DNA Copy Number Variations | Proto-Oncogene Proteins c-met - genetics | Receptor, Epidermal Growth Factor - metabolism | Comparative Genomic Hybridization | Glioblastoma - genetics | Receptor, Platelet-Derived Growth Factor alpha - genetics | Base Sequence | Glioblastoma - pathology | Adult | Female | Glioblastoma - metabolism | Mosaicism | Aged | Tyrosine | Medical colleges | Platelet-derived growth factor | Gene mutations | Brain tumors | Genes | Phenols | Development and progression | Phosphotransferases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
by Richeldi, Luca and Costabel, Ulrich and Selman, Moises and Kim, Dong Soon and Hansell, David M and Nicholson, Andrew G and Brown, Kevin K and Flaherty, Kevin R and Noble, Paul W and Raghu, Ganesh and Brun, Michèle and Gupta, Abhya and Juhel, Nolwenn and Klüglich, Matthias and du Bois, Roland M
The New England Journal of Medicine, ISSN 0028-4793, 09/2011, Volume 365, Issue 12, pp. 1079 - 1087
Idiopathic pulmonary fibrosis is characterized by rapid loss of vital capacity, disability, and death. There are no effective treatments. Although this study... 
INJURY | LUNG | MEDICINE, GENERAL & INTERNAL | THERAPY | QUALITY-OF-LIFE | CLINICAL-COURSE | Enzyme Inhibitors - adverse effects | Humans | Middle Aged | Male | Alanine Transaminase - blood | Enzyme Inhibitors - therapeutic use | Vital Capacity | Indoles - adverse effects | Aspartate Aminotransferases - blood | Liver - drug effects | Adult | Female | Indoles - therapeutic use | Aged | Idiopathic Pulmonary Fibrosis - physiopathology | Idiopathic Pulmonary Fibrosis - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Dosage and administration | Pulmonary fibrosis | Drug therapy | Patient outcomes | Statistical analysis | Writers | Disease | Liver | Lung diseases | Fibrosis | Clinical medicine | Growth factors | Protein-tyrosine kinase | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
by Chu, Tammy F, BA and Rupnick, Maria A, MD and Kerkela, Risto, MD and Dallabrida, Susan M, PhD and Zurakowski, David, PhD and Nguyen, Lisa, BS and Woulfe, Kathleen, BS and Pravda, Elke, BS and Cassiola, Flavia, PhD and Desai, Jayesh, MD and George, Suzanne, MD and Harris, David M, PhD and Ismail, Nesreen S, BS and Chen, Jey-Hsin, MD and Schoen, Frederick J, MD and Van den Abbeele, Annick D, MD and Demetri, George D, MD and Force, Thomas, MD and Chen, Ming Hui, MD and Morgan, Jeffrey A
Lancet, The, ISSN 0140-6736, 2007, Volume 370, Issue 9604, pp. 2011 - 2019
Summary Background Sunitinib, a multitargeted tyrosine-kinase inhibitor, which is approved by both US and European Commission regulatory agencies for clinical... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THERAPY | METASTATIC BREAST-CANCER | FACTOR RECEPTORS | MONOCLONAL-ANTIBODY | ANTITUMOR-ACTIVITY | GASTROINTESTINAL STROMAL TUMORS | RENAL-CELL CARCINOMA | SU11248 | HYPOTHYROIDISM | ENDOTHELIAL GROWTH-FACTOR | Humans | Middle Aged | Rats | Stroke Volume - drug effects | Male | Antineoplastic Agents - therapeutic use | Animals | Indoles - adverse effects | Multicenter Studies as Topic | Antineoplastic Agents - adverse effects | Gastrointestinal Stromal Tumors - drug therapy | Pyrroles - adverse effects | Female | Indoles - therapeutic use | Blood Pressure - drug effects | Mice | Retrospective Studies | Pyrroles - therapeutic use | Heart Failure - chemically induced | Protein-Tyrosine Kinases - antagonists & inhibitors | Research | Cardiovascular diseases | Drug therapy | Gastrointestinal tumors | Risk factors | Side effects | Heart attacks | Hospitals | Toxicity | Clinical trials | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells
by Bellodi, Cristian and Lidonnici, Maria Rosa and Hamilton, Ashley and Helgason, G. Vignir and Soliera, Angela Rachele and Ronchetti, Mattia and Galavotti, Sara and Young, Kenneth W and Selmi, Tommaso and Yacobi, Rinat and Van Etten, Richard A and Donato, Nick and Hunter, Ann and Dinsdale, David and Tirrò, Elena and Vigneri, Paolo and Nicotera, Pierluigi and Dyer, Martin J and Holyoake, Tessa and Salomoni, Paolo and Calabretta, Bruno
Journal of Clinical Investigation, ISSN 0021-9738, 05/2009, Volume 119, Issue 5, pp. 1109 - 1123
Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become standard first-line therapy for patients with chronic myeloid leukemia... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, RESEARCH & EXPERIMENTAL | MALIGNANT GLIOMA-CELLS | BLAST CRISIS | CLINICAL RESISTANCE | BCR-ABL MUTATIONS | ENDOPLASMIC-RETICULUM | CYTOCHROME-C RELEASE | CASPASE ACTIVATION | IMATINIB RESISTANCE | CHRONIC MYELOID-LEUKEMIA | Transcription Factor CHOP - genetics | Neoplastic Stem Cells - cytology | Gene Expression - drug effects | Calcium - metabolism | Gene Expression - genetics | Microtubule-Associated Proteins - metabolism | Neoplastic Stem Cells - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Endoplasmic Reticulum - metabolism | Antineoplastic Agents - therapeutic use | Autophagy - physiology | Thiazoles - therapeutic use | Autophagy - drug effects | Chloroquine - pharmacology | Neoplastic Stem Cells - metabolism | RNA Interference | Endoplasmic Reticulum - drug effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Macrolides - pharmacology | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Dasatinib | Chloroquine - therapeutic use | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Mice, Inbred C3H | Xenograft Model Antitumor Assays | Fusion Proteins, bcr-abl - genetics | Animals | Cell Death - physiology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Benzamides | Macrolides - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Causes of | Physiological aspects | Genetic aspects | Chronic myeloid leukemia | Research | Drug therapy | Phagocytosis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor: A Meta-analysis
by Lee, June-Koo and Hahn, Seokyung and Kim, Dong-Wan and Suh, Koung Jin and Keam, Bhumsuk and Kim, Tae Min and Lee, Se-Hoon and Heo, Dae Seog
JAMA, ISSN 0098-7484, 04/2014, Volume 311, Issue 14, pp. 1430 - 1437
IMPORTANCE Current guidelines recommend both epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and cytotoxic chemotherapy drugs as... 
1ST-LINE ERLOTINIB | TRIAL | MEDICINE, GENERAL & INTERNAL | GEFITINIB | MULTICENTER | RANDOMIZED PHASE-3 | ADENOCARCINOMA | 2ND-LINE TREATMENT | OPEN-LABEL | MUTATIONS | EGFR | Disease-Free Survival | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Protein Kinase Inhibitors - therapeutic use | Humans | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Randomized Controlled Trials as Topic | Chemotherapy | Care and treatment | Research | Lung cancer, Non-small cell | Health aspects | Tyrosine metabolism | Cancer | Inhibitor drugs | Kinases | Lung cancer | Meta-analysis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors
: Focus on Pyrimidines, Pyridines and Pyrroles
by Di Gion, Paola and Kanefendt, Friederike and Lindauer, Andreas and Scheffler, Matthias and Doroshyenko, Oxana and Fuhr, Uwe and Wolf, Jürgen and Jaehde, Ulrich
Clinical Pharmacokinetics, ISSN 0312-5963, 9/2011, Volume 50, Issue 9, pp. 551 - 603
Pyrimidine (imatinib, dasatinib, nilotinib and pazopanib), pyridine (sorafenib) and pyrrole (sunitinib) tyrosine kinase inhibitors (TKIs) are multi-targeted... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Nilotinib | Dasatinib | Pyridines | Imatinib | Pyrroles | Receptor-protein-tyrosine- kinase-antagonists | Metabolism | Pyrimidines | Sunitinib | Sorafenib | Antineoplastics | Pharmacokinetics | Pazopanib | Cancer | CHRONIC MYELOGENOUS LEUKEMIA | PHASE-I TRIAL | ACUTE LYMPHOBLASTIC-LEUKEMIA | PHARMACOLOGY & PHARMACY | IMATINIB MESYLATE GLEEVEC | MAIN METABOLITE CGP-74588 | GASTROINTESTINAL STROMAL TUMORS | RENAL-CELL CARCINOMA | CHRONIC MYELOID-LEUKEMIA | ENDOTHELIAL GROWTH-FACTOR | CANCER RESISTANCE PROTEIN | Protein Kinase Inhibitors - pharmacokinetics | Pyrroles - metabolism | Pyrroles - pharmacokinetics | Pyrimidines - blood | Humans | Pyridines - pharmacokinetics | Male | Pyrroles - blood | Pyrimidines - pharmacology | Protein Kinase Inhibitors - blood | Pyrimidines - metabolism | Pyridines - blood | Pyrroles - pharmacology | Drug Interactions | Pyridines - metabolism | Pyrimidines - pharmacokinetics | Female | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Protein Kinase Inhibitors - metabolism | Antimitotic agents | Usage | Antineoplastic agents | Health aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights